Sarepta Therapeutics, Inc. cash flow to debt ratio of -19.76% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Sarepta Therapeutics, Inc.'s free cash flow has increased -12.84% from $-352.74M last year to $-307.45M, signaling increasing performance

Sarepta Therapeutics, Inc.'s debt to equity ratio is 0.68, which means that the company's assets are unhealthy financed, signaling financial risk.

Sarepta Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.88 last year to 0.68 today, signaling strengthened financials

Sarepta Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Sarepta Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Sarepta Therapeutics, Inc.'s profit margin has decreased (155.99%) in the last year from 12.37% to -6.93%, signaling decreasing performance

Sarepta Therapeutics, Inc.'s short-term assets of $2.54B exceed its short-term liabilities of $1.10B

Sarepta Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Sarepta Therapeutics, Inc.'s return on equity of -9.96%, is lower than 15.00%, indicating bad performance

Sarepta Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Sarepta Therapeutics, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Sarepta Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Sarepta Therapeutics, Inc. has negative free cash flow, indicating cash burn

Sarepta Therapeutics, Inc.'s yearly earnings has decreased 403.27% since last year from $235.24M to $-713.41M, signaling decreasing performance

Sarepta Therapeutics, Inc.'s yearly revenue has increased 15.58% since last year from $1.90B to $2.20B, signaling increasing performance

ROIC -5.33% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Sarepta Therapeutics, Inc.'s 3-year revenue CAGR of 33.06% is positive, indicating growing revenue over the past 3 years

Sarepta Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Sarepta Therapeutics, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Sarepta Therapeutics, Inc. has insufficient data to evaluate this check.

Sarepta Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sarepta Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Sarepta Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Sarepta Therapeutics, Inc. is overvalued relative to its fair value price of -121.49 based on Earnings Fair Value model

Sarepta Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sarepta Therapeutics, Inc. has a price-to-book ratio of 1.19x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Sarepta Therapeutics, Inc. has a price-to-sales ratio of 0.92x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue